Last reviewed · How we verify
Iopamidol injection 76%
Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.
Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.
At a glance
| Generic name | Iopamidol injection 76% |
|---|---|
| Also known as | Isovue |
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Iodinated contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It distributes throughout the vascular system and extracellular space, allowing visualization of blood vessels, organs, and tissues during angiography, CT, and other imaging studies. The 76% formulation refers to the iodine concentration by weight.
Approved indications
- Contrast enhancement for angiography and vascular imaging
- Contrast enhancement for computed tomography (CT) imaging
- Contrast enhancement for urography and other radiographic procedures
Common side effects
- Contrast-induced nephropathy
- Allergic reaction (mild to severe)
- Nausea and vomiting
- Flushing and warmth sensation
- Hypersensitivity reactions
Key clinical trials
- Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients (PHASE4)
- Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopamidol injection 76% CI brief — competitive landscape report
- Iopamidol injection 76% updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI